Looking for insulin rebound, Novo Nordisk wins delayed FDA nod for ultrafast Fiasp
admin 29th September 2017 Uncategorised 0For Novo Nordisk and its new fast-acting mealtime insulin, a second try at the FDA gatekeepers was enough to secure an approval. The drugmaker’s Fiasp won its U.S. nod on Friday, setting Novo up for a new launch in a crowded field.
More: Looking for insulin rebound, Novo Nordisk wins delayed FDA nod for ultrafast Fiasp
Source: fierce